Cipaglucosidase alfa clinical trials
Also written ATB200.
How each study uses cipaglucosidase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cipaglucosidase alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Sept 2023 · POMBILITI · BLA 761204 (FDA, Drugs@FDA)
- European Union
- 20 Mar 2023 · Pombiliti · EMEA/H/C/005703 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test cipaglucosidase alfa, phase 3 first.
- Mar 2027ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDPhase 3 · Amicus Therapeutics
- Jul 2027A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Phase 3 · Amicus Therapeutics
Studies
Open first, then newest update. How each study uses cipaglucosidase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18RecruitingPhase 3Amicus TherapeuticsNCT04808505Written as Cipaglucosidase alfa
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDActive, not recruitingPhase 3Amicus TherapeuticsNCT03911505Written as Cipaglucosidase Alfa
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)CompletedPhase 3Amicus TherapeuticsNCT04138277Written as ATB200
- First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221CompletedPhase 1/2Amicus TherapeuticsNCT02675465Written as ATB200
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseaseCompletedPhase 3Amicus TherapeuticsNCT03729362Written as Cipaglucosidase Alfa
Codes
What other systems call cipaglucosidase alfa · ClinicalTrials.gg INT002136
- MeSH (NLM) C000731755cipaglucosidase alfaOne source NLM
- UNII (FDA) 4SED7F4BSGCIPAGLUCOSIDASE ALFAConfirmed FDA, NLM
- NCI Thesaurus C175059Cipaglucosidase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731755 | cipaglucosidase alfa | One source NLM |
| UNII (FDA) | 4SED7F4BSG | CIPAGLUCOSIDASE ALFA | Confirmed FDA, NLM |
| NCI Thesaurus | C175059 | Cipaglucosidase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.